Natural mutants of HIV CTL epitopes with enhanced immunogenicity as potential vaccine candidates.
Natural mutants of HIV CTL epitopes with enhanced immunogenicity as potential vaccine candidates.
复制标题
HIV CTL 表位的天然突变体具有增强的免疫原性，可作为潜在的候选疫苗。
DOI：
10.1007/978-0-387-73657-0_166
复制
发表时间：
2009
影响因子：
--
通讯作者：
Wilson,DarcyB
中科院分区：
文献类型：
--
作者：
Blondelle,SylvieE;Moya,Rosa;Schroder,Kim;Osawa,Keiko;Wilson,DarcyB
艾滋病毒/艾滋病在许多发展中国家仍然是一种严重的、最终致命的流行病。抗逆转录病毒药物在治疗方面取得了重大进展，但仍然存在重大问题。这些治疗昂贵且难以应用，特别是对于缺乏足够资金和基础设施的发展中国家，不能消除所有病毒，因此需要终身治疗方案，具有显著的毒副作用，并且在某些地区由于病毒突变而变得不那么有效。仍然非常需要确定预防新的艾滋病毒感染的有效措施，特别是在世界上艾滋病毒大流行的地区。基于疫苗发展的历史，免疫接种将提供控制HIV/AIDS传播的最有效和可负担的长期方法，这在生物医学研究界仍然是一个强烈的共识。强的细胞毒性T淋巴细胞（CTL）应答被认为对于有效的人类免疫缺陷病毒（HIV）疫苗的发展是重要的;它们的益处已经在猴免疫缺陷病毒（SIV）疫苗接种研究和自然感染中得到证实[1，2]。我们的主要目标之一是确定优化的，高免疫原性的肽，用于HIV感染的预防性或治疗性疫苗的设计。我们的策略来自于这样的假设，即HIV的罕见突变CTL表位可能比常见的更具有免疫原性，并且这些HIV表位的罕见突变序列可能更有效地产生针对罕见和常见突变序列的交叉反应性抗HIV CTL应答。
HIV/AIDS remains a serious, ultimately lethal pandemic disease in much of the developing world. Significant treatment advances have been made with antiretroviral agents, but major problems remain. These treatments are expensive and difficult to apply especially for developing world nations that lack adequate finances and infrastructure, do not eliminate all virus and therefore require life long treatment regimens, carry significant toxic side effects and in some quarters becoming less effective due to viral mutation. There remains a major need to identify effective measures to prevent new HIV infections, especially in areas of the world where it is a pandemic. Based on the history of vaccine development, it remains a strong consensus in the biomedical research community that immunization will provide the most effective and affordable long term-approach to controlling the spread of HIV/AIDS.Strong cytotoxic T-lymphocyte (CTL) responses are thought to be important for the development of an effective human immunodeficiency virus (HIV) vaccine; their benefit has been established in simian immunodeficiency virus (SIV) vaccination studies and in natural infections [1, 2]. One of our major goals is to identify optimized, highly immunogenic peptides for the design of prophylactic or therapeutic vaccines for HIV infection. Our strategy derives from the hypothesis that the rarer mutant CTL epitopes of HIV may be more immunogenic than the common ones and that these rarer mutant sequences of HIV epitopes might be more effective in generating cross reactive anti-HIV CTL responses against both the rare and common mutant sequences.